Comparable stake leader
Chiliz Group Ltd.
SEC ownership of Processa Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001533743.
Disclosed value leader
Chiliz Group Ltd.
Comparable rows
15/29
Latest evidence
29 May 2026
- Public ticker
- PCSA on Nasdaq
- Parsed ownership sources
- 13D/G, 13F, and 3/4/5
- Largest SEC-reported holder
- Chiliz Group Ltd.
- Latest 13D/G holder
- Chiliz Group Ltd.
- Latest parsed ownership date
- 29 May 2026
- Issuer CIK
- 0001533743
- Issuer location
- Vero Beach, FL
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Processa Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Chiliz Group Ltd.
Disclosed value leader
Chiliz Group Ltd.
Comparable rows
15/29
Latest evidence
29 May 2026
13D/G
13F
3/4/5
Lead comparable stake: 13%
14 rows are not safely comparable across share classes.
13D/G row: Chiliz Group Ltd.
Showing 1-8 of 29 holder rows.
Quick read
Chiliz Group Ltd. leads the comparable SEC ownership view at 13%.
15 of 29 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Chiliz Group Ltd.'s linked filing trail.
Comparable ownership
Top 5
Chiliz Group Ltd.
13%
INTRACOASTAL CAPITAL, LLC
8.1%
CVI Investments, Inc.
7%
ARMISTICE CAPITAL, LLC
5%
3i, LP
4.9%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 29 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Chiliz Group Ltd. |
13D/G
HX Entertainment Ltd
|
13%
|
$959,722
305,644 shares
|
$0 | 13 Feb 2026 |
| INTRACOASTAL CAPITAL, LLC |
13D/G
Mitchell P. Kopin
|
8.1%
|
$644,000
200,000 shares
|
$0 | 31 Dec 2025 |
| CVI Investments, Inc. |
13D/G
|
7%
|
$24,000
200,000 shares
|
-$576,000 | 31 Mar 2026 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
5%
|
$608,206
2,644,376 shares
|
+$475,127 | 30 Jun 2025 |
| 3i, LP |
13D/G
|
4.9%
|
$504,583
1,681,944 shares
|
$0 | 17 Jun 2025 |
| Connective Capital Management, LLC |
13F
Company
|
3%
|
$178,608
70,736 shares
|
— | 31 Mar 2026 |
| Stonepine Capital Management, LLC |
13F
Company
|
2.3%
|
$138,875
55,000 shares
|
— | 31 Mar 2026 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
1.1%
|
$62,768
24,908 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$158,043.
Buys
$158,043
Insiders: 9
Sells
$0
Insiders: 0
Net
+$158,043
Shares: +58,032
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 58,032
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 58,032 | 0 | $158,043 | $0 | +$158,043 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-14 of 14 reporting-owner rows connected to Processa Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
14
Largest Forms 3/4/5 holder
David Young
Net 12M change
+$158,045
Latest report
29 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| David Young | Pres. Research & Development, Director | $93,127 | +$22,945 | +33% | Mixed | 29 May 2026 |
| Patrick Lin | Chief Business - Strategy Off | $70,569 | +$20,326 | +40% | Mixed | 29 May 2026 |
| Sian Bigora | Chief Development Officer | $68,758 | +$16,026 | +30% | Mixed | 30 Apr 2026 |
| Wendy Guy | Chief Administrative Officer | $68,730 | +$23,506 | +52% | Mixed | 29 May 2026 |
| George K. Ng | Chief Executive Officer, Director | $63,895 | +$32,779 | +105% | Mixed | 29 May 2026 |
| James H. Stanker | Chief Financial Officer | $61,609 | Mixed | 05 Apr 2024 | ||
| Robert Michael Floyd | Chief Operating Officer | $51,618 | Mixed | 09 Feb 2023 | ||
| Virgil Thompson | Director | $42,163 | Mixed | 27 Jun 2023 | ||
| Russell Skibsted | Chief Financial Officer | $33,528 | +$29,458 | +724% | Mixed | 29 May 2026 |
| Yorke Justin W. | Director | $11,248 | Mixed | 01 Oct 2025 | ||
| Khoso Baluch | Director | $5,893 | +$5,752 | +4079% | Filing P/S | 31 Mar 2026 |
| Geraldine Pannu | Director | $5,546 | +$5,253 | +1793% | Filing P/S | 31 Mar 2026 |
| James R. Neal | Director | $2,073 | +$2,000 | +2740% | Filing P/S | 31 Mar 2026 |
| Khalid Islam | Director | Mixed | 31 Mar 2022 |
Recent insider transactions for Processa Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| David Young | PCSA | Common Stock | Purchase | 11.6% | $4,590 | $2.57 | 1,786 | 17,131 | 29 May 2026 | Direct |
| Russell Skibsted | PCSA | Common Stock | Purchase | 27.1% | $5,890 | $2.57 | 2,292 | 10,758 | 29 May 2026 | Direct |
| George K. Ng | PCSA | Common Stock | Purchase | 27.2% | $5,472 | $2.57 | 2,129 | 9,970 | 29 May 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Purchase | 20.8% | $4,066 | $2.57 | 1,582 | 9,176 | 29 May 2026 | Direct |
| Wendy Guy | PCSA | Common Stock | Purchase | 22.8% | $4,701 | $2.57 | 1,829 | 9,840 | 29 May 2026 | Direct |
| George K. Ng | PCSA | Common Stock | Purchase | 30.7% | $5,474 | $2.97 | 1,843 | 7,841 | 15 May 2026 | Direct |
| David Young | PCSA | Common Stock | Purchase | 11.2% | $4,589 | $2.97 | 1,545 | 15,345 | 15 May 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Purchase | 22% | $4,066 | $2.97 | 1,369 | 7,594 | 15 May 2026 | Direct |
| Wendy Guy | PCSA | Common Stock | Purchase | 24.6% | $4,702 | $2.97 | 1,583 | 8,011 | 15 May 2026 | Direct |
| Russell Skibsted | PCSA | Common Stock | Purchase | 30.6% | $5,892 | $2.97 | 1,984 | 8,466 | 15 May 2026 | Direct |
| Sian Bigora | PCSA | Common Stock | Purchase | 35.8% | $5,341 | $2.71 | 1,971 | 7,481 | 30 Apr 2026 | Direct |
| David Young | PCSA | Common Stock | Purchase | 14.1% | $4,589 | $2.69 | 1,706 | 13,813 | 30 Apr 2026 | Direct |
| Russell Skibsted | PCSA | Common Stock | Purchase | 50.8% | $5,891 | $2.69 | 2,190 | 6,498 | 30 Apr 2026 | Direct |
| George K. Ng | PCSA | Common Stock | Purchase | 51.1% | $5,471 | $2.69 | 2,034 | 6,013 | 30 Apr 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Purchase | 32% | $4,065 | $2.69 | 1,511 | 6,236 | 30 Apr 2026 | Direct |
| Wendy Guy | PCSA | Common Stock | Purchase | 37.2% | $4,702 | $2.69 | 1,748 | 6,441 | 30 Apr 2026 | Direct |
| George K. Ng | PCSA | Common Stock | Purchase | 86.3% | $5,474 | $2.97 | 1,843 | 3,979 | 15 Apr 2026 | Direct |
| George K. Ng | PCSA | Common Stock | Purchase | 86.3% | $5,474 | $2.97 | 1,843 | 3,979 | 15 Apr 2026 | Direct |
| David Young | PCSA | Common Stock | Purchase | 14.6% | $4,589 | $2.97 | 1,545 | 12,107 | 15 Apr 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Purchase | 40.8% | $4,066 | $2.97 | 1,369 | 4,725 | 15 Apr 2026 | Direct |
| Wendy Guy | PCSA | Common Stock | Purchase | 50.9% | $4,702 | $2.97 | 1,583 | 4,693 | 15 Apr 2026 | Direct |
| Sian Bigora | PCSA | Common Stock | Purchase | 48.5% | $5,343 | $2.97 | 1,799 | 5,510 | 15 Apr 2026 | Direct |
| Russell Skibsted | PCSA | Common Stock | Purchase | 85.4% | $5,892 | $2.97 | 1,984 | 4,308 | 15 Apr 2026 | Direct |
| George K. Ng | PCSA | Common Stock | Purchase | $5,415 | $2.54 | 2,136 | 2,136 | 31 Mar 2026 | Direct | |
| James R. Neal | PCSA | Common Stock | Purchase | 2720.7% | $2,000 | $2.54 | 789 | 818 | 31 Mar 2026 | Direct |
| David Young | PCSA | Common Stock | Purchase | 20.7% | $4,588 | $2.54 | 1,810 | 10,562 | 31 Mar 2026 | Direct |
| Russell Skibsted | PCSA | Common Stock | Purchase | $5,891 | $2.54 | 2,324 | 2,324 | 31 Mar 2026 | Direct | |
| Geraldine Pannu | PCSA | Common Stock | Purchase | 1786.2% | $5,253 | $2.54 | 2,072 | 2,188 | 31 Mar 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Purchase | 91.4% | $4,064 | $2.54 | 1,603 | 3,356 | 31 Mar 2026 | Direct |
| Wendy Guy | PCSA | Common Stock | Purchase | 147.6% | $4,700 | $2.54 | 1,854 | 3,110 | 31 Mar 2026 | Direct |
| Sian Bigora | PCSA | Common Stock | Purchase | 131.4% | $5,341 | $2.54 | 2,107 | 3,711 | 31 Mar 2026 | Direct |
| Khoso Baluch | PCSA | Common Stock | Purchase | 4051.8% | $5,752 | $2.54 | 2,269 | 2,325 | 31 Mar 2026 | Direct |
| Patrick Lin | PCSA | Common Stock | Options Exercise | 12.4% | 193 | 1,753 | 01 Jan 2026 | Direct | ||
| Patrick Lin | PCSA | Common Stock | Options Exercise | -100% | -193 | 0 | 01 Jan 2026 | Direct | ||
| Wendy Guy | PCSA | Common Stock | Options Exercise | 18.2% | 193 | 1,256 | 01 Jan 2026 | Direct | ||
| Wendy Guy | PCSA | Restricted Stock Units | Options Exercise | -100% | -193 | 0 | 01 Jan 2026 | Direct | ||
| Sian Bigora | PCSA | Common Stock | Options Exercise | 18.4% | 249 | 1,604 | 01 Jan 2026 | Direct | ||
| Sian Bigora | PCSA | Restricted Stock Units | Options Exercise | -100% | -249 | 0 | 01 Jan 2026 | Direct | ||
| David Young | PCSA | Common Stock | Options Exercise | 0.56% | 49 | 8,752 | 01 Jan 2026 | Direct | ||
| David Young | PCSA | Restricted Stock Units | Options Exercise | -100% | -49 | 0 | 01 Jan 2026 | Direct | ||
| James R. Neal | PCSA | Stock Options (Right to Buy) | Award | 300,000 | 300,000 | 01 Oct 2025 | Direct | |||
| James R. Neal | PCSA | Restricted Stock Units | Award | 100,000 | 100,000 | 01 Oct 2025 | Direct | |||
| Khoso Baluch | PCSA | Stock Options (Right to Buy) | Award | 300,000 | 300,000 | 01 Oct 2025 | Direct | |||
| Khoso Baluch | PCSA | Restricted Stock Units | Award | 100,000 | 100,000 | 01 Oct 2025 | Direct | |||
| Geraldine Pannu | PCSA | Stock Options (Right to Buy) | Award | 300,000 | 300,000 | 01 Oct 2025 | Direct | |||
| Geraldine Pannu | PCSA | Restricted Stock Units | Award | 100,000 | 100,000 | 01 Oct 2025 | Direct | |||
| Justin W. Yorke | PCSA | Stock Options (Right to Buy) | Award | 300,000 | 300,000 | 01 Oct 2025 | Direct | |||
| Justin W. Yorke | PCSA | Restricted Stock Units | Award | 100,000 | 100,000 | 01 Oct 2025 | Direct | |||
| Wendy Guy | PCSA | Stock Options (Right to Buy) | Award | 150,000 | 150,000 | 01 Oct 2025 | Direct | |||
| Wendy Guy | PCSA | Restricted Stock Units | Award | 50,000 | 50,000 | 01 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.